The SUGAR-DIP trial; oral medication versus insulin for diabetes in pregnancy

No registrations found.

Ethical review Positive opinion **Status** Recruiting

Health condition type -

Study type Interventional

Summary

ID

NL-OMON25358

Source

NTR

Brief title

SUGAR-DIP

Health condition

Gestational diabetes Diabetes gravidarum Zwangerschapsdiabetes

Sponsors and support

Primary sponsor: University Medical Center Utrecht **Source(s) of monetary or material Support:** ZonMw

Intervention

Outcome measures

Primary outcome

Number of infants born large-for-gestational-age (LGA)

Secondary outcome

1 - The SUGAR-DIP trial; oral medication versus insulin for diabetes in pregnancy 3-05-2025

- Maternal hypoglycemia
- Primary / secondary caesarean section
- Pregnancy related hypertensive disorders: pregnancy induced hypertension, preeclampsia
- Preterm delivery (<37 weeks of gestation)
- Neonatal hypoglycemia: moderate (serum glucose <2.6 mmol/l), severe (serum glucose<2.0 mmol/l)
- Neonatal hyperbilirubinemia requiring phototherapy
- Neonatal Medium care / NICU admission

Study description

Study objective

Oral antidiabetic medication in the form of metformin and if needed supplementary glibenclamide are a safe and effective first choice treatment strategy for gestational diabetes.

Study design

- Maternal hypoglycemia: study period until 6 weeks postpartum
- Primary / secondary caesarean section: delivery
- Pregnancy related hypertensive disorders: study period until 6 weeks postpartum
- Preterm delivery: delivery
- Neonatal hypoglycemia: delivery until discharge
- Neonatal hyperbilirubinemia requiring phototherapy: delivery intil 6 weeks postpartum
- Neonatal Medium care / NICU admission: delivery until 6 weeks postpartum
- fetal umbilical cord blood C-peptide: delivery
- maternal HbA1c measures: study intake, week 30 and 35 of pregnancy

Intervention

2 - The SUGAR-DIP trial; oral medication versus insulin for diabetes in pregnancy 3-05-2025

Intervention: metformin and if needed supplementary glibenclamide

Comparator: insulin

Contacts

Public

UMC Utrecht, WKZ

L. de Wit Lundlaan 6

Utrecht 3584 EA
The Netherlands
0031 88 755 4913
Scientific
UMC Utrecht, WKZ

L. de Wit Lundlaan 6

Utrecht 3584 EA The Netherlands 0031 88 755 4913

Eligibility criteria

Inclusion criteria

- Aged 18 years or over
- Singleton pregnancy
- Diagnosis of GDM as per national guidelines
- Indication for pharmacological treatment of GDM
- Gestational age between 16 and 34 weeks
- Ability to understand Dutch or English

- Ability to provide written informed consent

Exclusion criteria

- Known pre-existent type 1 or type 2 diabetes mellitus
- Severe medical or psychiatric comorbidities
- Serious liver disease or kidney failure, or any other condition with contraindications for the use of either metformin or glibenclamide
- Pregnancy with a fetus affected by major congenital birth defects and/or chromosomal abnormalities

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 29-11-2016

Enrollment: 810

Type: Anticipated

Ethics review

Positive opinion

Date: 29-11-2016

Application type: First submission

4 - The SUGAR-DIP trial; oral medication versus insulin for diabetes in pregnancy 3-05-2025

Study registrations

Followed up by the following (possibly more current) registration

ID: 47522

Bron: ToetsingOnline

Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL5953 NTR-old NTR6134

CCMO NL57195.041.16 OMON NL-OMON47522

Study results